A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •1. Types of psoriasis other than chronic plaque-type psoriasis.
• •2. Drug-induced psoriasis.
• •3. Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.
• •4. Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.
• •5. History of repeated chronic infection, had any serious infection or systemic infection within 2 months before screening.
• •6. Progressive or uncontrolled symptoms or signs of circulatory, respiratory, digestive, neuropsychiatric or psychological, hematological, endocrine and other systems before randomization.
• •7. History of malignant tumour within 5 years before screening.
• •8. Previous or current autoimmune diseases.
• •9. Allergic to any component of the investigational drug, or have had severe allergic reactions to monoclonal antibodies.